ACOR Acorda Therapeutics Inc

Price (delayed)

$10.17

Market cap

$12.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.51

Enterprise value

$165.14M

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults ...

Highlights
The company's EPS has surged by 99% YoY and by 73% QoQ
ACOR's net income has soared by 85% YoY and by 24% QoQ
Acorda Therapeutics's debt has decreased by 4% YoY but it has increased by 2.5% QoQ
ACOR's quick ratio is down by 25% from the previous quarter and by 16% YoY
The company's equity fell by 22% YoY and by 13% QoQ

Key stats

What are the main financial stats of ACOR
Market
Shares outstanding
1.24M
Market cap
$12.63M
Enterprise value
$165.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
0.11
EV/EBIT
13.26
EV/EBITDA
3.74
EV/Sales
1.49
Earnings
Revenue
$111.12M
EBIT
$12.45M
EBITDA
$44.18M
Free cash flow
-$2.12M
Per share
EPS
-$1.51
Free cash flow per share
-$1.71
Book value per share
$47.47
Revenue per share
$89.47
TBVPS
$67.9
Balance sheet
Total assets
$366.34M
Total liabilities
$307.39M
Debt
$186.09M
Equity
$58.96M
Working capital
$27.43M
Liquidity
Debt to equity
3.16
Current ratio
1.59
Quick ratio
0.98
Net debt/EBITDA
3.45
Margins
EBITDA margin
39.8%
Gross margin
87.2%
Net margin
-14.4%
Operating margin
-18.4%
Efficiency
Return on assets
-4.2%
Return on equity
-21.5%
Return on invested capital
6.6%
Return on capital employed
3.9%
Return on sales
11.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACOR stock price

How has the Acorda Therapeutics stock price performed over time
Intraday
-3.05%
1 week
2.73%
1 month
6.38%
1 year
1,546.96%
YTD
1,226.46%
QTD
-32.15%

Financial performance

How have Acorda Therapeutics's revenue and profit performed over time
Revenue
$111.12M
Gross profit
$96.87M
Operating income
-$20.43M
Net income
-$15.95M
Gross margin
87.2%
Net margin
-14.4%
ACOR's net income has soared by 85% YoY and by 24% QoQ
Acorda Therapeutics's net margin has surged by 83% YoY and by 20% QoQ
Acorda Therapeutics's operating income has surged by 60% YoY and by 8% QoQ
ACOR's operating margin has surged by 55% year-on-year and by 3.2% since the previous quarter

Growth

What is Acorda Therapeutics's growth rate over time

Valuation

What is Acorda Therapeutics stock price valuation
P/E
N/A
P/B
0.21
P/S
0.11
EV/EBIT
13.26
EV/EBITDA
3.74
EV/Sales
1.49
The company's EPS has surged by 99% YoY and by 73% QoQ
ACOR's P/B is 27% below its 5-year quarterly average of 0.3 but 10% above its last 4 quarters average of 0.2
The company's equity fell by 22% YoY and by 13% QoQ
ACOR's price to sales (P/S) is 70% lower than its 5-year quarterly average of 0.4 but 20% higher than its last 4 quarters average of 0.1
The company's revenue fell by 10% YoY and by 5% QoQ

Efficiency

How efficient is Acorda Therapeutics business performance
The company's return on sales has surged by 130% YoY and by 38% QoQ
ACOR's ROIC has soared by 128% year-on-year and by 32% since the previous quarter
Acorda Therapeutics's ROA has soared by 83% YoY and by 24% from the previous quarter
Acorda Therapeutics's ROE has soared by 77% YoY and by 19% from the previous quarter

Dividends

What is ACOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACOR.

Financial health

How did Acorda Therapeutics financials performed over time
ACOR's total assets is 19% greater than its total liabilities
Acorda Therapeutics's current ratio has decreased by 26% QoQ and by 7% YoY
ACOR's quick ratio is down by 25% from the previous quarter and by 16% YoY
Acorda Therapeutics's debt to equity has increased by 23% YoY and by 18% from the previous quarter
The company's equity fell by 22% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.